Independent Pharmaceutical Research
China’s pharmaceutical industry, documented.
Fineline BioInsights publishes fully-sourced, English-language research on the world’s second-largest drug market — annual archives and disease-area reports written for executives, BD teams and investors who need to understand the market beyond the headlines.
Latest Publication
CPIA 2025 · Annual Archive
The Catalogue
Our publications.
A growing library of research on China’s pharmaceutical industry. Each volume is built on primary regulatory sources, official approval data and verified transaction records.
China Pharmaceutical Innovation Archive 2025
The definitive annual reference on China’s pharmaceutical innovation landscape — regulatory reforms, NRDL negotiations, license-out deals and payment reform, across 52 fully-sourced pages.
Report on Cardiovascular Health and Diseases in China 2025
A dedicated deep-dive into China’s cardiovascular health and disease landscape — epidemiology, clinical practice and the market for cardiovascular therapeutics. In production.
New disease-area and special reports are published as research completes. The catalogue grows with each edition — subscribe below to be notified of new releases.
Featured · The 2025 Annual Archive
A market that moved from follower to source.
The 2025 Archive distills a full year of China’s pharmaceutical innovation into one referenced volume.
Methodology
Research you can trace.
Primary regulatory sources
NMPA approval records, NHSA negotiation outcomes and official policy documents — read in the original, not through secondhand summaries.
Official approval data
Every approval, designation and reimbursement decision is drawn from the regulator’s own published data.
Verified transaction records
Licensing deals are checked against company disclosures and verified records. Where a figure is provisional, the report says so.
“We do not publish speculation.”Fineline BioInsights · Research Methodology
Editorial Team
The people behind the research.
Karia Olsen
Pharmaceutical industry analyst with 15 years of experience. Master’s degree in Pharmacy from Fudan University; a decade at a multinational pharmaceutical consultancy.
Emily Zhang
Leona Zeng
Fineline BioInsights is the pharmaceutical research and publishing division of Fineline Information & Technology. All reports are company publications; copyright belongs to Fineline Information & Technology.
Research Areas
What we cover.
- 01
Industry & Regulation
NMPA approval trends, priority review, breakthrough designations, patent term extension and the reform history behind today’s market.
- 02
Market Access & Payment
NRDL negotiations, volume-based procurement and the pricing dynamics shaping patient access.
- 03
Disease-area Reports
Dedicated deep-dives into specific therapeutic areas — beginning with cardiovascular health and diseases.
- 04
BD, Policy & Trade
License-out transactions, NewCo structures, industrial policy and U.S.–China trade developments.
Insights
Research insights, forthcoming.
Short, sourced analysis of the developments that matter — drawn from our reports and the primary data behind them. New insights and report releases are announced to subscribers first.
